Akeso has announced a collaboration with Summit Therapeutics and Pfizer.

康方生物宣布与Summit Therapeutics和辉瑞达成合作。

Ivonescimab is a PD-1/VEGF bispecific immunotherapy developed by Akeso. In Summit Therapeutics’ licensed territories—including the United States, Canada, Europe, Japan, Central and South America, the Middle East, and Africa—it is referred to as SMT112.

伊沃尼西单抗（Ivonescimab）是康方生物（Akeso）开发的一种PD-1/VEGF双特异性免疫疗法。在Summit Therapeutics的授权区域内——包括美国、加拿大、欧洲、日本、中南美洲、中东和非洲——它被称为SMT112。

Ivonescimab has received marketing approval in China for the treatment of EGFR-mutated, locally advanced, or metastatic non-squamous non-small cell lung cancer (NSCLC) after EGFR TKI therapy.

伊沃西单抗已在中国获得营销批准，用于治疗EGFR突变、局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）在EGFR TKI治疗后。

Akeso is conducting six registrational trials comparing ivonescimab to PD-1/L1 therapies, alongside multiple clinical studies covering 17 indications, including gastrointestinal cancer, hepatocellular carcinoma, and colorectal cancer.

康方生物正在进行六项注册试验，将依沃西与PD-1/L1疗法进行对比，同时开展多项临床研究，涵盖包括胃肠道癌、肝细胞癌和结直肠癌在内的17种适应症。

The collaboration aims to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with several of Pfizer's antibody-drug conjugates (ADCs) for treating solid tumours.

该合作旨在评估PD-1/VEGF双特异性抗体ivonescimab与辉瑞的几种抗体药物偶联物（ADC）联合治疗实体瘤的效果。

The partnership is intended to explore the potential of these drug combinations to improve treatment options for patients with high medical needs. The studies will assess the safety and effectiveness of ivonescimab when combined with Pfizer’s vedotin ADCs in distinct tumour types.

该合作伙伴关系旨在探索这些药物组合在改善高医疗需求患者的治疗选择方面的潜力。这些研究将评估伊沃尼单抗与辉瑞的维多汀ADC联合使用时在不同肿瘤类型中的安全性和有效性。

Under the agreement, Summit will provide ivonescimab, while Pfizer will oversee the clinical trials. Both companies will retain the rights to their respective products.

根据协议，Summit公司将提供伊沃西单抗，而辉瑞公司将负责监督临床试验。两家公司都将保留各自产品的权利。

The trials are expected to commence in mid-2025, with further details to be disclosed later.

试验预计将于2025年年中开始，更多细节将在稍后披露。

Source: akesobio.com

来源：akesobio.com